Table 4 Univariate analyses of treatment variables for the outcome of treatment success versus treatment failure, loss to follow-up, or death, using complete case analysis
Variable | Treatment outcome [n (%)] | Odds of treatment success versus failure, loss to follow-up, or death [cOR (95% CI)] | p-value | |
|---|---|---|---|---|
Success | Failure, loss to follow-up, or death | |||
Age (n = 612) | n/aa | n/aa | 0.99 (0.97–1.00) | 0.013 |
Gender (n = 612) | ||||
Female | 112 (75.7%) | 36 (24.3%) | 1.00 (reference) | 0.003 |
Male | 289 (62.3%) | 175 (37.7%) | 0.53 (0.35–0.81) | |
Previous treatment (n = 594) | ||||
No | 65 (62.5%) | 39 (37.5%) | 1.00 (reference) | 0.456 |
Yes | 325 (66.3%) | 165 (33.7%) | 1.18 (0.76–1.83) | |
Financially supported through SHI (n = 426) | ||||
No | 72 (62.6%) | 43 (37.4%) | 1.00 (reference) | 0.310 |
Yes | 211 (67.8%) | 100 (32.2%) | 1.26 (0.81–1.97) | |
Diabetes (n = 424) | ||||
No | 256 (68.6%) | 117 (31.4%) | 1.00 (reference) | 0.053 |
Yes | 28 (54.9%) | 23 (45.1%) | 0.56 (0.31–1.01) | |
Heart disease (n = 424) | ||||
No | 275 (67.7%) | 131 (32.3%) | 1.00 (reference) | 0.125 |
Yes | 9 (50.0%) | 9 (50.0%) | 0.48 (0.19–1.23) | |
HIV (n = 500) | ||||
No | 319 (68.8%) | 145 (31.2%) | 1.00 (reference) | 0.001 |
Yes | 15 (41.7%) | 21 (58.3%) | 0.33 (0.16–0.65) | |
Kidney disease (n = 424) | ||||
No | 283 (67.1%) | 139 (32.9%) | 1.00 (reference) | 0.616 |
Yes | 1 (50.0%) | 1 (50.0%) | 0.49 (0.03–7.91) | |
Liver disease (n = 424) | ||||
No | 273 (67.6%) | 131 (32.4%) | 1.00 (reference) | 0.248 |
Yes | 11 (55.0%) | 9 (45.0%) | 0.59 (0.24–1.45) | |
Malnutrition (n = 424) | ||||
No | 277 (67.4%) | 134 (32.6%) | 1.00 (reference) | 0.312 |
Yes | 7 (53.8%) | 6 (46.2%) | 0.46 (0.19–1.71) | |
Psychiatric disorder (n = 424) | ||||
No | 274 (66.5%) | 138 (33.5%) | 1.00 (reference) | 0.237 |
Yes | 10 (83.3%) | 2 (16.7%) | 2.52 (0.54–11.65) | |
Respiratory disorderb (n = 424) | ||||
No | 256 (68.8%) | 116 (31.2%) | 1.00 (reference) | 0.034 |
Yes | 28 (53.8%) | 24 (46.2%) | 0.53 (0.29–0.95) | |
Substance abuse (n = 424) | ||||
No | 277 (68.1%) | 130 (31.9%) | 1.00 (reference) | 0.027 |
Yes | 7 (41.2%) | 10 (58.8%) | 0.33 (0.12–0.88) | |
Other comorbidityc (n = 424) | ||||
No | 277 (67.4%) | 134 (32.6%) | 1.00 (reference) | 0.312 |
Yes | 7 (53.8%) | 6 (46.2%) | 0.56 (0.19–1.71) | |
Infection site (n = 598) | ||||
Pulmonary | 378 (65.4%) | 200 (34.6%) | 1.00 (reference) | 0.777 |
Extrapulmonary | 9 (75.0%) | 3 (25.0%) | 1.59 (0.43–5.92) | 0.492 |
Both | 5 (62.5%) | 3 (37.5%) | 0.88 (0.21–3.72) | 0.864 |
Antibiotic resistance (n = 409) | ||||
RR-/MDR-TB | 255 (71.4%) | 102 (28.6%) | 1.00 (reference) | 0.000 |
Pre-XDR or XDR-TB | 24 (47.2%) | 28 (52.8%) | 0.34 (0.19–0.62) | |
Initial sputum (smear) positivity (n = 584) | ||||
No | 149 (69.6%) | 65 (30.4%) | 1.00 (reference) | 0.152 |
Yes | 235 (63.7%) | 134 (36.3%) | 0.77 (0.54–1.10) | |
Smear conversion after 2 months (n = 557) | ||||
No | 41 (53.2%) | 36 (46.8%) | 1.00 (reference) | 0.002 |
Yes | 341 (71.0%) | 139 (29.0%) | 2.15 (1.32–3.51) | |
Culture conversion after 2 months (n = 526) | ||||
No | 75 (62.5%) | 45 (37.5%) | 1.00 (reference) | 0.071 |
Yes | 289 (71.2%) | 117 (28.8%) | 1.48 (0.97–2.27) | |
Smear conversion after 4 months (n = 518) | ||||
No | 6 (37.5%) | 10 (62.5%) | 1.00 (reference) | 0.005 |
Yes | 364 (72.5%) | 138 (27.5%) | 4.40 (1.57–12.33) | |
Culture conversion after 4 months (n = 509) | ||||
No | 15 (44.1%) | 19 (55.9%) | 1.00 (reference) | 0.000 |
Yes | 351 (73.9%) | 124 (26.1%) | 3.59 (1.77–7.27) | |
At least one side effect experienced during inpatient treatment (n = 418) | ||||
No | 261 (67.4%) | 126 (32.6%) | 1.00 (reference) | 0.077 |
Yes | 16 (51.6%) | 15 (48.4%) | 0.52 (0.25–1.08) | |
At least one side effect experienced during outpatient treatment (n = 545) | ||||
No | 294 (66.2%) | 150 (33.8%) | 1.00 (reference) | 0.120 |
Yes | 75 (74.3%) | 26 (25.7%) | 1.47 (0.90–2.40) | |